Search

Displaying results 2671 - 2680 of 10000 in total
  1. Drug

    Aminophenazone

    go.drugbank.com/drugs/DB01424
    ApprovedWithdrawn

    In biomedical applications, radiolabelled (13C-labeled) aminophenazone has been used in breath tests to measure the cytochrome P-450 metabolic activity in liver function tests. … Aminophenazone is a pyrazolone with analgesic, anti-inflammatory, and antipyretic properties that carries a risk of agranulocytosis.

  2. Drug

    Pyruvic acid

    go.drugbank.com/drugs/DB00119
    ApprovedInvestigationalNutraceutical

    An intermediate compound in the metabolism of carbohydrates, proteins, and fats. In thiamine deficiency, its oxidation is retarded and it accumulates in the tissues, especially in nervous structures.

  3. Drug

    Estradiol dienanthate

    go.drugbank.com/drugs/DB13955
    ApprovedVet approvedWithdrawn

    Estradiol dienanthate is not currently available in any commercially available products in Canada or the US. … various tissues including in the breasts, uterus, ovaries, skin, prostate, bone, fat, and brain.

  4. Drug

    Cevimeline

    go.drugbank.com/drugs/DB00185
    Approved

    It is indicated by the Food and Drug Administration for the treatment of dry mouth associated with Sjögren's syndrome. … Cevimeline is a parasympathomimetic agent that act as an agonist at the muscarinic acetylcholine receptors M1 and M3.

  5. Drug

    Cosibelimab

    go.drugbank.com/drugs/DB15770
    ApprovedInvestigational

    Cosibelimab is a human IgG1 lambda monoclonal antibody directed against programmed death ligand-1 (PD-L1). … On December 13, 2024, cosibelimab was approved by the FDA for the treatment of metastatic or locally advanced cutaneous squamous cell carcinoma [L52690] as the first approved anti-PD-L1 therapy in the

  6. Drug

    Phenindione

    go.drugbank.com/drugs/DB00498
    ApprovedInvestigational

    Phenindione has actions similar to warfarin, but it is now rarely employed because of its higher incidence of severe adverse effects. (From Martindale, The Extra Pharmacopoeia, 30th ed, p234)

  7. Drug

    Hyaluronidase (human recombinant)

    go.drugbank.com/drugs/DB06205
    ApprovedInvestigational

    [L13338] The action of hyaluronidase was first described in 1936, and named in 1939. … [A199047] Hyaluronidase was first used in prescription products in the United States on 5 May 2004.[L13338]

  8. Drug

    Iodoform

    go.drugbank.com/drugs/DB13813
    ApprovedInvestigationalVet approvedWithdrawn

    It is a relatively water-insoluble yellow solid that is chemically reactive in free-radical reactions [A32890]. … Iodoform is soluble in fatty acids and decomposes releasing iodine in nascent state (96,7% of iodine) when in contact with secretions or endodontic infections [A32893].

  9. Drug

    Dihydroergocristine

    go.drugbank.com/drugs/DB13345
    Approved

    Dihydroergocristine is part of the ergoloid mixture products.[L2637] It is a semisynthetic ergot alkaloid and thus, it is characterized by a structural skeleton formed by an alkaloid ergoline.

  10. Drug

    Hydroflumethiazide

    go.drugbank.com/drugs/DB00774
    ApprovedWithdrawn

    A thiazide diuretic with actions and uses similar to those of hydrochlorothiazide. (From Martindale, The Extra Pharmacopoeia, 30th ed, p822)